Henry Ford Cancer Institute-Downriver

Summary

Henry Ford Cancer Institute-Downriver is a medical facility located in Trenton, Michigan. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Cancer, Pancreatic Cancer and other specialties. Henry Ford Cancer Institute-Downriver is involved with conducting 120 clinical trials across 298 conditions. There are 4 research doctors associated with this hospital, such as Ding Wang, Haythem Y. Ali, Eleanor M. Walker, and Thomas J. Doyle.

Top PIs

Clinical Trials running at Henry Ford Cancer Institute-Downriver

Bladder Cancer

Breast Cancer

Lung Cancer

Prostate Cancer

Pancreatic Cancer

Breast cancer

Kidney Cancer

Bladder Carcinoma

Colorectal Cancer

Oropharyngeal Carcinoma

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Multi-Cancer Detection Test

for Cancer

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).

Recruiting

1 award

N/A

1 criteria

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria